Shattuck Labs (STTK) Shares Outstanding (Weighted Average) (2019 - 2026)
Shattuck Labs (STTK) reported Shares Outstanding (Weighted Average) of $38.4 million for Q1 2026, down 24.56% year-over-year from $51.0 million in Q1 2025, and down 44.75% quarter-over-quarter from $69.6 million in Q4 2025.
Shattuck Labs (STTK) Shares Outstanding (Weighted Average) (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $38.4 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $38.4 million, down 24.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.4 million (down 24.56% YoY), and the FY2025 annual result was $69.6 million, up 37.09% from the prior year.
- Shares Outstanding (Weighted Average) eased to $38.4 million in Q1 2026 per STTK's latest filing, from $69.6 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $72.2 million in Q3 2025 and troughed at $3.1 million in Q4 2023.
- A 5-year average of $43.4 million and a median of $42.5 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) plunged 92.7% in 2024, then surged 1544.21% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $42.4 million in 2022, then sank by 92.68% to $3.1 million in 2023, then soared by 1536.93% to $50.8 million in 2024, then jumped by 37.09% to $69.6 million in 2025, then sank by 44.75% to $38.4 million in 2026.
- Business Quant data shows STTK's Shares Outstanding (Weighted Average) at $38.4 million in Q1 2026, $69.6 million in Q4 2025, and $72.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Shattuck Labs | 190.32 Mn | 190.32 Mn | - | 38.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.45 Mn |
| Dec 31, 2025 | 69.58 Mn |
| Sep 30, 2025 | 72.18 Mn |
| Jun 30, 2025 | 50.98 Mn |
| Mar 31, 2025 | 50.97 Mn |
| Dec 31, 2024 | 50.76 Mn |
| Sep 30, 2024 | 50.73 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 50.57 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 42.48 Mn |
| Jun 30, 2023 | 42.45 Mn |
| Mar 31, 2023 | 42.44 Mn |
| Dec 31, 2022 | 42.38 Mn |
| Sep 30, 2022 | 42.37 Mn |
| Jun 30, 2022 | 42.38 Mn |
| Mar 31, 2022 | 42.36 Mn |
| Dec 31, 2021 | 42.03 Mn |
| Sep 30, 2021 | 41.95 Mn |
| Jun 30, 2021 | 41.84 Mn |